PICKERING GRANT sold $105K of PCVX (indirect holdings)
PICKERING GRANT (CHIEF EXECUTIVE OFFICER) sold 2,000 indirectly-held shares of Vaxcyte, Inc. (PCVX) at $52.50 ($0.10M total) across 2 trades on 2026-06-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO’s open-market sale of 2,000 shares at $52.50 under a pre-arranged 10b5-1 plan is typically treated as lower-signal than discretionary selling; it may modestly influence sentiment but does not change fundamentals by itself.
Market read
Traders may monitor PCVX for follow-on insider activity, but the disclosed transaction alone is unlikely to drive a major repricing.
What to watch
Check for any concurrent insider buys/sales, changes in trading plans, or upcoming company-specific events (earnings/clinical updates) that could dominate price action.
Background
The article is an SEC Form 4 insider transaction disclosure for Vaxcyte, Inc. (PCVX).
Ticker impact
Vaxcyte CEO Pickering Grant sold $105,000 of PCVX shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4; any impact would be short-lived.
The filing is a small, pre-arranged open-market sale by the CEO with no accompanying operational/regulatory/financial catalyst disclosed.
Market effects
Minimal; this is company-specific insider trading with no sector-wide regulatory/clinical read-across.
None indicated.
None indicated.
Counterpoint
Because it’s a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish fundamentals; traders may ignore it unless paired with other negative catalysts.
Key entities
- issuerVaxcyte, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderPickering Grant
CEO and director who sold shares under a 10b5-1 plan.
